Remunix develops novel therapeutics specifically targeting autoimmune diseases. The company's platform leverages new biological insights into immune cell activation and checkpoints. This research is focused on creating a new class of antibody-based drugs designed to safely and selectively reduce autoimmune responses.
Funding
$16M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Autoimmune diseases result from an overactive immune system attacking the body's own tissues, leading to chronic inflammation and tissue damage. Current treatments often broadly suppress the immune system, increasing the risk of infections and other side effects. There is a need for therapies that can selectively modulate the immune response to alleviate autoimmune symptoms without causing widespread immunosuppression.
Solution
Remunix is developing a new class of antibody-based therapeutics designed to selectively attenuate the autoimmune response. By targeting specific immune cell activation pathways and checkpoints, Remunix's approach aims to re-establish immune homeostasis in patients with autoimmune diseases. These novel therapeutics are designed to safely and selectively modulate the immune system, reducing inflammation and tissue damage while minimizing off-target effects. The company's approach is based on new insights into the fundamental biology of immune cell activation and checkpoints.
Target Audience
The primary target audience includes patients suffering from various autoimmune diseases, as well as physicians specializing in rheumatology, immunology, and related fields.
Features
- Antibody-based therapeutics targeting immune cell activation pathways
- Selective modulation of the immune response to minimize off-target effects
- Designed to re-establish immune homeostasis in autoimmune diseases